Altimmune Stock Today
| ALT Stock | USD 6.86 0.15 2.24% |
Performance2 of 100
| Odds Of DistressLess than 42
|
Altimmune is selling for under 6.86 as of the 18th of January 2025; that is 2.24 percent increase since the beginning of the trading day. The stock's last reported lowest price was 6.73. Altimmune has about a 42 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 19th of December 2024 and ending today, the 18th of January 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 6th of October 2005 | Category Healthcare | Classification Health Care |
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland. Altimmune operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 71.12 M outstanding shares of which 23.69 M shares are presently shorted by investors with about 7.06 days to cover. More on Altimmune
Moving against Altimmune Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Altimmune Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO, Director | Vipin Garg | |||||||||||||||||||||||||||||||||||||||||||||
| Old Names | [Altran Technologies S.A, Analytica Ltd, Alturas Minerals Corp.] | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Stock Exchange Of, NASDAQ Composite, NASDAQ Biotechnology, NASDAQ Health Care, HNX, Bucharest Plus Index, HNX MidSmall Cap, HNX Manufacturing, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAltimmune can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Altimmune's financial leverage. It provides some insight into what part of Altimmune's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Altimmune (ALT) is traded on NASDAQ Exchange in USA. It is located in 910 Clopper Road, Gaithersburg, MD, United States, 20878 and employs 59 people. Altimmune is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a total capitalization of 487.91 M. Altimmune runs under Biotechnology sector within Health Care industry. The entity has 71.12 M outstanding shares of which 23.69 M shares are presently shorted by investors with about 7.06 days to cover.
Altimmune has about 184.76 M in cash with (75.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.81.
Check Altimmune Probability Of Bankruptcy
Ownership AllocationAltimmune holds a total of 71.12 Million outstanding shares. Over half of Altimmune's outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Altimmune Ownership Details
Altimmune Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Swiss National Bank | 2024-09-30 | 139.5 K |
Altimmune Historical Income Statement
Altimmune Stock Against Markets
Altimmune Corporate Management
| Scot Roberts | Chief Scientific Officer | Profile | |
| Tony BS | Vice Management | Profile | |
| Richard MBA | Chief Officer | Profile | |
| Kent BSEE | Co Controller | Profile | |
| Andrew MS | Corporate Controller | Profile | |
| Bertrand Georges | Chief Officer | Profile |
Already Invested in Altimmune?
The danger of trading Altimmune is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Altimmune is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Altimmune. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Altimmune is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Altimmune Stock Analysis
When running Altimmune's price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.